News

Recordings

- Oct. 28, 2024
News
CLINICAL TRIALS
IND Enabling
Phase I
Phase II
Phase III
Recurrent or Progressive High-grade Glioma, (NCT06737146)
Sponsors:
Suzhou Maximum Bio-tech Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine